VAXCYTE INC
PCVXNASDAQTrading Snapshot
- Day Range
- $59.58 – $63.94
- 52-Week Range
- $39.87 – $90.75
- Volume (shares)
- 2,212,599
- Avg Volume (shares)
- —
- Shares Outstanding
- 152.2M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-7.64
- Dividend Yield
- —
- Dilution (1yr)
- +10.8%
VAXCYTE INC
PCVX
StockOtter · stockotter.spaceAbout VAXCYTE INC
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst h
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings
Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale
What happened Vaxcyte, Inc. (NASDAQ: PCVX) closed a financing on October 9, 2026, and sold $575 million of 1.50% convertible senior notes due 2032. The notes are senior unsecured obligations. The initial conversion rate
Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74, for a total transact
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS